ClelandLGJamesMJStampLKPenglisPS. COX-2 inhibition and thrombotic tendency: A need for surveillance. Med J Aust2001; 175: 214–7.
2.
BingRJLomnickaM. Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events?J Am Coll Cardiol2002; 39: 521–2.
3.
CroffordLJOatesJCMcCuneWJGuptaSKaplanMJCatella-LawsonF. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: A report of four cases. Arthritis Rheum2000; 43: 1891–6.
4.
MukherjeeDTopolEJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA2001; 286: 954–9.
5.
NaranjoCABustoUSellersEMSandorPRuizIRobertsEA. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 329–45.
